【美股异动 | 溃疡性结肠炎疗法obefazimod取得积极数据 Abivax S.A.(ABVX.US)暴涨超40%】智通财经APP获悉，周二，Abivax S.A.(ABVX.US)盘初暴涨超40%，现报133.70美元。消息面上，Abivax周一公布了在研溃疡性结肠炎疗法obefazimod的额外III期维持治疗数据。数据显示，在初始诱导治疗失败或在维持治疗期间复发的患者中，该疗法仍持续带来临床获益。这些结果还扩大了该药物的安全性数据库，因为公司计划在今年晚些时候提交美国监管申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.